七麦数据

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health.

FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results.

Scores enhance FibroScan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

• Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast.
• Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.
• Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

FibroScan® is the non-invasive solution for comprehensive management of liver health.

Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.

- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.

FibroScan® is the non-invasive solution for comprehensive management of liver health.

Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.

- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.

FibroScan® is the non-invasive solution for comprehensive management of liver health.

Fibroscan® provides unique and patented biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 2500 peer-reviewed publications and 60+ international guidelines.

myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way :

The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting Fibroscan® examination results.
Scores enhance Fibroscan® liver disease assessment with biological markers.
Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.

- Agile™3+ is an aid to identify NAFLD patients with advanced fibrosis by combining VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins.

- Agile™4 is an aid to early identify NAFLD patients with cirrhosis by combining VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin.

- Fast™ is an aid to identify at risk NASH patients defined as NASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (NAFLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast™.

FibroScan® is the first non-invasive medical device that streamlines your management of chronic liver disease, from screening to follow-up and prognosis.

Reference solution providing patented dual function capability VCTE™ (fibrosis) and CAP™ (steatosis), the FibroScan® benefits from a worldwide clinical legitimacy and is recommended in the guidelines of leading organizations.

myFibroScan app is the best companion to enlarge the suite of diagnosis tools based on FibroScan® results:

- interpret FibroScan® examination results to assess fibrosis stage and steatosis grade, according to scientific publications, etiology and examination results VCTE™ and CAP™ with the Interpretation Guide tool

- assess the probability of active NASH with the new FAST™ score, combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST). Best-in-class diagnostic performance and broad applicability demonstrated on 1,300 patients from different clinical setting and geographical origin: consistent 0.85-0.90 average AUROCs performance

FibroScan® is the first non-invasive medical device that streamlines your management of chronic liver disease, from screening to follow-up and prognosis.

Reference solution providing patented dual function capability VCTE™ (fibrosis) and CAP™ (steatosis), the FibroScan® benefits from a worldwide clinical legitimacy and is recommended in the guidelines of leading organizations.

myFibroScan app is the best companion to enlarge the suite of diagnosis tools based on FibroScan® results:

- interpret FibroScan® examination results to assess fibrosis stage and steatosis grade, according to scientific publications, etiology and examination results VCTE™ and CAP™ with the Interpretation Guide tool

- assess the probability of active NASH with the new FAST™ score, combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST). Best-in-class diagnostic performance and broad applicability demonstrated on 1,300 patients from different clinical setting and geographical origin: consistent 0.85-0.90 average AUROCs performance

FibroScan® is the first non-invasive medical device that streamlines your management of chronic liver disease, from screening to follow-up and prognosis.

Reference solution providing patented dual function capability VCTE™ (fibrosis) and CAP™ (steatosis), the FibroScan® benefits from a worldwide clinical legitimacy and is recommended in the guidelines of leading organizations.

myFibroScan app is the best companion to enlarge the suite of diagnosis tools based on FibroScan® results:

- interpret FibroScan® examination results to assess fibrosis stage and steatosis grade, according to scientific publications, etiology and examination results VCTE™ and CAP™ with the Interpretation Guide tool

- assess the probability of active NASH with the new FAST™ score, combining FibroScan® biomarkers of liver fibrosis (VCTE™) and steatosis (CAP™) with blood biomarker of liver inflammation (AST). Best-in-class diagnostic performance and broad applicability demonstrated on 1,300 patients from different clinical setting and geographical origin: consistent 0.85-0.90 average AUROCs performance